MM&M's New Drug Dossier - combining authoritative promotional and clinical insights on the latest new molecular entities into one indispensable resource for the pharmaceutical marketer.
Click on the sample dossier below to see the full range of information included.
A potent combination:
MM&M has leveraged the strength
of two of the best known names in healthcare publishing to launch its New Drug Dossier. Powered by Monthly Prescribing Reference (MPR), this
online resource uniquely combines the authoritative clinical information of MPR with the marketing savvy of MM&M into one tool designed to provide
pharmaceutical marketing professionals with a new level of business
Every time a new drug
is approved, a dossier will be compiled, and subscribers will be alerted to it
An in-depth look at newly approved drugs: Dossiers for newly approved drugs* include a wealth of promotional intelligence, like agency rosters, marketing strategy/execution and recent MM&M news coverage. In addition, analyst comment, financial data and other drugs in the pipeline are provided by healthcare marketing research companies such as the GfK US Healthcare Companies, IMS Health and Adis R&D Insight, part of Wolters Kluwer Health.
A subscription grants
marketers access to the complete dossier archive.
Powered by Monthly Prescribing Reference:
MM&M New Drug Dossier also offers in-depth clinical information from MPR: class, indication, active ingredient, pharmacology, clinical trials, adverse reactions and more. To view a sample dossier, click here.
Sign up now for a year's subscription and get:
- The special introductory rate of $350
- Unlimited access to the MM&M New Drug Dossier archive
- Email Alerts for all new** drugs
Customers will receive log-in information within one business day of subscribing.
* Initial database includes new molecular entities launched in 2007.
** New molecular entities, combinations and select new indications